Trials / Active Not Recruiting
Active Not RecruitingNCT04784247
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
A Pilot Study of Lenvatinib Plus Pembrolizumab in Patients With Advanced Sarcoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether combining the study drugs, lenvatinib and pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that cannot be removed with surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | 20mg daily (two 10mg lenvatinib capsules) taken orally |
| DRUG | Pembrolizumab | (200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. |
Timeline
- Start date
- 2021-03-18
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2021-03-05
- Last updated
- 2026-01-27
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04784247. Inclusion in this directory is not an endorsement.